Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2007

01.10.2007 | Original Article

Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours

verfasst von: I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz, M. Schäfer, T. Schilling, S. Haufe, T. Herrmann, U. Haberkorn

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Neuroendocrine tumours (NETs) can be imaged with scintigraphy using radiolabelled somatostatin analogues. The aim of our study was to compare the value of 68Ga-DOTATOC PET and 111In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations.

Methods

Twenty-seven NET patients were prospectively examined. 68Ga-DOTATOC PET and 111In-DTPAOC SPECT were performed using standard techniques. Treatment was not applied in between. Mean and maximum standardised uptake values (SUVs) were calculated for PET findings. Tumour/non-tumour ratios were calculated for SPECT findings. Findings were compared by a region-by-region analysis and verified with histopathology, CT and MRI within 21 days.

Results

SUVs of positive lesions on 68Ga-DOTATOC PET ranged from 0.7 to 29.3 (mean SUV) and from 0.9 to 34.4 (maximum SUV). Tumour/non-tumour ratios on 111In-DTPAOC SPECT ranged from 1.8 to 7.3. In imaging lung and skeletal manifestations, 68Ga-DOTATOC PET was more efficient than 111In-DTPAOC SPECT. All discrepant lung findings and 77.8% of discrepant osseous findings were verified as true positive PET interpretations. In regional comparison of liver and brain, 68Ga-DOTATOC PET and 111In-DTPAOC SPECT were identical. In lymph nodes, the pancreas and the gastro-intestinal system, different values of the two techniques were not indicated in regional analyses. In a single patient, surgical interventions were changed on the basis of 68Ga-DOTATOC PET findings.

Conclusion

68Ga-DOTATOC PET is superior to 111In-DTPAOC SPECT in the detection of NET manifestations in the lung and skeleton and similar for the detection of NET manifestations in the liver and brain. 68Ga-DOTATOC PET is advantageous in guiding the clinical management.
Literatur
1.
Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005;37 12:722–8.PubMedCrossRef
2.
Papotti M, Kuma U, Volante M, Pecchiono C, Patel YC. Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid. Clin Endocrinol 2001;54:641–9.CrossRef
3.
Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H. Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today 2002;32 8:690–4.PubMedCrossRef
4.
Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002;440 5:461–75.PubMedCrossRef
5.
Kaltsas G, Mukherjee JJ, Grossman AB. The value of radiolabeled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Clin Endocrinol 2001;55:575–87.CrossRef
6.
Kaltsas G, Rockall A, Papadogias D, Reznek R, Grossman AB. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol 2004;151:15–27.PubMedCrossRef
7.
Gibril F, Reynolds JC, Doppmann JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Int Med 1996;125 1:26–34.PubMed
8.
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Maecke HR, Haberkorn U, et al. Comparison of the pharmacokinetics of 68Ga-DOTATOC and 18F-FDG in patients with metastatic neuroendocrine tumours (NET) scheduled for 90Y -DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33 4:460–6.PubMedCrossRef
9.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 2000;27:273–82.CrossRef
10.
Kowalski J, Henze M, Schumacher J, Maecke HR, Hofmann H, Haberkorn U. Evaluation of positron emission tomography imaging using 68Ga DOTA-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imag Biol 2003;5 1:42–8.CrossRef
11.
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur J Nucl Med Mol Imaging. 2001;28 12:1751–7.CrossRef
12.
Heppeler A, Froidevaux S, Mäcke HR. Radiometal-labeled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974–81.CrossRef
13.
Schuhmacher J, Maier-Borst W. A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. Appl Radiat Isotopes 1981;32:31–6.CrossRef
14.
Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, et al. Localization of neuroendocrine tumours with [111In]-DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MRI imaging. QJM 1998;91 4:295–301.PubMedCrossRef
15.
Martin WH, Delbeke D, Patton JA, Sandler MP. Detection of malignancies with SPECT versus PET, with 2-(fluorine-18)fluoro-2-deoxy-D-glucose. Radiology 1996;198 1:225–31.PubMed
16.
Arita T, Kuramitsu T, Kawamura M, Matsumoto T, Matsunaga N, Sugi K, et al. Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. Thorax 1995;50:1267–9.PubMedCrossRef
17.
Einstein DM, Singer AA, Chilcote WA, Desai RK. Abdominal lymphadenopathy: spectrum of CT findings. RadioGraphics 1991;11:457–72.PubMed
18.
Gross BH, Glatzer GM, Orringer MB. Bronchogenic carcinoma metastatic to normal-sized nodes: frequency and significance. Radiology 1988;166:71–4.PubMed
19.
Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1–5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999;48 1:77–85.PubMedCrossRef
20.
Casini Raggi C, Calabro A, Renzi D, Briganti V, Cianchi F, Messerini L, et al. Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002;8 2:419–27.PubMed
21.
Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Doebert N, et al. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 2003;30 2:37–40.PubMedCrossRef
Metadaten
Titel
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
verfasst von
I. Buchmann
M. Henze
S. Engelbrecht
M. Eisenhut
A. Runz
M. Schäfer
T. Schilling
S. Haufe
T. Herrmann
U. Haberkorn
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0450-1

Weitere Artikel der Ausgabe 10/2007

European Journal of Nuclear Medicine and Molecular Imaging 10/2007 Zur Ausgabe

Original Article

Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

Original Article

Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study

Image of the month

Diagnosis of endoneural sciatic nerve invasion by uterine cervical epidermoid cancer using [18F]FDG-PET/CT

Editorial commentary

Predicting response to chemoradiotherapy in rectal and oesophageal cancer with 18F-FDG: prognostic value and possible role in patient management

Original Article

Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence

Original Article

Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer